Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating
04:07am, Friday, 10'th Oct 2025
Axsome Therapeutics is transitioning into a leading neuroscience company with three marketed drugs and a robust late-stage pipeline. Q2 2025 saw 72% YoY revenue growth, driven by Auvelity and Sunosi,
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
07:00am, Thursday, 09'th Oct 2025
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
07:00am, Tuesday, 07'th Oct 2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
10:46am, Tuesday, 30'th Sep 2025
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
04:10am, Tuesday, 30'th Sep 2025
Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods.
Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
01:53am, Thursday, 18'th Sep 2025
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 8:40 AM EDT Company Participants Mark Jacobson - Chief Operating
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
07:00am, Wednesday, 17'th Sep 2025
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer's disease agitation, narcolepsy, and obstructive sleep apnea Six poster presentations showcase cl
Axsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
05:49pm, Monday, 08'th Sep 2025
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Mark Jacobson - Chief Operating Officer Nick Pizzie
Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
12:31pm, Wednesday, 03'rd Sep 2025
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
01:31pm, Friday, 29'th Aug 2025
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 27'th Aug 2025
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings
01:40pm, Tuesday, 05'th Aug 2025
Axsome Therapeutics, Inc. AXSM reported better-than-expected second-quarter financial results on Monday.
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
12:41pm, Tuesday, 05'th Aug 2025
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript
02:50pm, Monday, 04'th Aug 2025
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Ari Maizel - Chief Commercial Officer Darren Opland - Corporate Participant Her
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings
10:31am, Monday, 04'th Aug 2025
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to
